Core Insights - Spartan Capital Securities, LLC successfully completed two private placements for Lipella Pharmaceuticals Inc., raising a total of $875,500 through the offerings of Series B non-voting convertible preferred stock [1][2][3] Company Overview - Lipella Pharmaceuticals, led by CEO Jonathan Kaufman, focuses on developing safe and effective therapies to address significant unmet medical needs [2][3] - Spartan Capital Securities serves as a premier investment banking firm, providing a range of advisory services and capital raising expertise [7] Transaction Details - The proceeds from the private placements will be utilized to advance Lipella's clinical pipeline and for general corporate purposes [2] - The transactions were completed under customary closing conditions, with Sichenzia Ross Ference Carmel LLP and Sullivan & Worcester LLP providing legal counsel [3][4] Regulatory Information - The common shares and related warrants from the private placements have not been registered under the Securities Act of 1933, and cannot be offered or sold in the U.S. without registration or an exemption [5][6]

Core Insights - Spartan Capital Securities LLC successfully completed a private placement for Lipella Pharmaceuticals Inc., raising $1,722,000 through the sale of up to 6,000,000 Series B non-voting convertible preferred stock [1][2][3] Company Overview - Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on addressing significant unmet medical needs with safe and effective therapies [2][3] - Jonathan Kaufman, PhD, serves as the CEO of Lipella Pharmaceuticals, leading the company's efforts in advancing its clinical pipeline [2] Transaction Details - The private placement closed on December 16, 2024, and the proceeds will support Lipella's clinical pipeline and general corporate purposes [2] - Spartan Capital Securities acted as the sole placement agent, highlighting its role in driving impactful investment opportunities [3] Legal and Compliance - Further details regarding the transaction will be available in Lipella's Form 8-K, which will be filed with the U.S. Securities and Exchange Commission [4] - The common shares and related warrants have not been registered under the Securities Act of 1933, and may not be offered or sold in the U.S. without registration or an applicable exemption [5]

Core Insights - Spartan Capital Securities LLC successfully completed a private placement for Lipella Pharmaceuticals Inc., raising $1,722,000 through the sale of up to 6,000,000 Series B non-voting convertible preferred stock [1][2][3] Group 1: Transaction Details - The private placement closed on December 16, 2024, and the proceeds will support Lipella's clinical pipeline and general corporate purposes [2] - Spartan Capital Securities acted as the sole placement agent for this transaction, highlighting its role in facilitating impactful investment opportunities [3] Group 2: Company Background - Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on addressing significant unmet medical needs with safe and effective therapies [2] - Spartan Capital Securities, LLC is a full-service investment banking firm known for its expertise in capital raising, strategic advisory, and asset management [7]

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus Peer-reviewed article highlights potential treatment for OLP with focus on localized drug deliveryPITTSBURGH, Dec. 03, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical ...

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group PITTSBURGH, November 21, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a lipo ...

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC). Lipella Pharmaceuticals, a cl ...

Core Insights - Lipella Pharmaceuticals has reported positive early tolerability results from its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP), indicating that the treatment is well tolerated with no unpleasant taste [1][2][4] - LP-310 is a proprietary liposomal-tacrolimus formulation aimed at providing a more effective treatment for OLP, which currently has no FDA-approved pharmacotherapies [2][4] - The clinical trial is a multicenter, dose-ranging study evaluating the safety, tolerability, and efficacy of LP-310 at various doses, with five sites across the U.S. actively recruiting participants [3][4] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, particularly targeting diseases with significant unmet medical needs [5] - The company completed its initial public offering in December 2022, indicating a commitment to advancing its drug development pipeline [5]

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research a ...

Core Insights - Lipella Pharmaceuticals has introduced LP-20, a novel MRI contrast agent aimed at diagnosing interstitial cystitis and detecting bladder cancer, which will be presented at the 5th International Consultation on Interstitial Cystitis Japan [1][3] Group 1: Product Overview - LP-20 is designed to identify bladder permeability defects and is administered via catheter, utilizing advanced MRI technology to aid in the diagnosis of interstitial cystitis and bladder cancer progression [2][4] - The agent has completed preclinical and proof-of-concept human trials, showing potential as a rapid and cost-effective diagnostic solution [2][4] Group 2: Clinical Significance - The use of LP-20 represents a significant advancement in bladder diagnostics, offering a non-invasive alternative to traditional methods such as cystoscopy [4] - The innovative imaging technique addresses unmet needs in urology, potentially enhancing patient care and streamlining patient identification for clinical trials [3][4] Group 3: Company Background - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, particularly targeting diseases with significant morbidity and mortality [6]